Newegg commerce: Galkin family buys $5.8M in NEGG stock
Cantor Fitzgerald reiterated its Overweight rating and $15.00 price target on Cabaletta Bio Inc . (NASDAQ:CABA) Thursday, significantly above the current trading price of $1.80. According to InvestingPro data, analyst targets range from $3 to $28, with the company currently valued at $96 million. The firm maintained its positive outlook following meetings with the company’s team at the EULAR conference in Barcelona.
Cabaletta presented clinical data at the conference with three oral presentations covering 18 patients across lupus, myositis, and scleroderma conditions. The presentations included data from eight new patients not previously reported.
The efficacy results showed that 13 out of 15 patients (87%) with at least three months of follow-up were able to discontinue their background therapy. Safety data for the newly reported patients revealed only Grade 1 cytokine release syndrome in four of the eight patients, with no other remarkable safety issues.
Cantor Fitzgerald noted a disconnect between the enthusiasm of physicians and patients for Cabaletta’s therapy compared to the biotech investment community’s response. The firm’s analyst described the efficacy as "stellar" in their assessment.
Following a recent financing round, Cabaletta Bio is now funded through the second half of 2026, providing runway for continued development of its therapeutic programs. InvestingPro data confirms the company holds more cash than debt, though it’s burning through cash quickly. Get access to 12 additional ProTips and comprehensive financial analysis with an InvestingPro subscription.
In other recent news, Cabaletta Bio announced promising clinical data from its investigational cell therapy, rese-cel, which showed positive responses in patients with myositis, lupus, and systemic sclerosis. The company reported that most patients were able to discontinue immunomodulatory drugs and steroids, with favorable safety outcomes. Cabaletta has enrolled 51 patients and dosed 24 in its RESET clinical trial program, with plans to expand its trials further. Additionally, Cabaletta Bio initiated a public offering expected to raise approximately $100 million, involving 39.2 million shares of common stock and 10.8 million pre-funded warrants. The offering, priced at $2.00 per share with accompanying warrants, is managed by Jefferies, TD Cowen, and Cantor. H.C. Wainwright maintained a buy rating on Cabaletta Bio, citing the promising clinical data presented at the EULAR 2025 conference. The company is advancing discussions with the FDA for its therapies targeting autoimmune diseases. These developments highlight Cabaletta Bio’s ongoing efforts to advance its cell therapy programs and secure additional funding for its initiatives.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.